Kevin Lundquist

Kevin Lundquist is an experienced financial executive with a diverse background in leadership roles across various industries. Currently serving as Chief Financial Officer and Chief Operations Officer at Fieldpiece Instruments since January 2024, Kevin previously held the position of Chief Financial Officer at Abzena, where responsibilities included strategic financial direction and IPO preparation for a rapidly growing CDMO. Prior to that, Kevin was Vice President of Finance at Revance Therapeutics, overseeing multiple financial operations and managing a team of 38 professionals. Kevin's tenure at Genentech involved leading finance for global pharmaceutical biologics operations, while at Caterpillar Inc., Kevin served as Chief Financial Officer for the Japan market and held other significant finance roles. Kevin's early career included various finance positions at Abbott. Kevin holds a Bachelor of Science in Accounting and Finance from the University of Utah and a Master’s in Business Administration with a focus on International Finance from Utah State University.